Tetraphase Pharmaceuticals Inc (TTPH)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

480 ARSENAL WAY WATERTOWN, MA 02472

Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various antibiotics for the treatment of serious and life-threatening multi-drug resistant infections through its chemistry technology. Its principal products include eravacycline, an intravenous and oral antibiotic that use as a empiric monotherapy has completed the Phase II clinical trials for the treatment of multi-drug resistant Gram-negative infections; and eravacycline oral formulation that is in Phase I clinical trials to treat complicated urinary tract infections in intravenous-to-oral step-down therapy.

Data as of 2019-12-02 22:12:21 -0500
Market Cap7.721 Million Shares Outstanding3.016 Million Avg 30-day Volume
P/E Ratio Dividend Yield EPS-29.71
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA 52-week High/Low37.9 / 2.26 Next Earnings Date Price to Cash FLow (P/CF)
Data provided by IEX Cloud
View SEC Filings from TTPH instead.

View recent insider trading info

Funds Holding TTPH (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TTPH BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LA JOLLA PHARMACEUTICAL CO

  • 10% Owner
4,822,360 2020-07-28 0

GAGE L PATRICK

  • Director
No longer subject to file 2020-07-28 0

MACDONALD GUY

  • Director
No longer subject to file 2020-07-28 0

STAHL MARIA D SEE REMARKS

  • Officer
No longer subject to file 2020-07-28 0

ARMISTICE CAPITAL, LLC

ARMISTICE CAPITAL MASTER FUND LTD.

BOYD STEVEN

  • Director
  • 10% Owner
No longer subject to file 2020-07-28 0

WATT CHRISTOPHER SENIOR VICE PRESIDENT, FINANCE

  • Officer
No longer subject to file 2020-07-28 0

EDWARDS LARRY G. SEE REMARKS

  • Officer
  • Director
No longer subject to file 2020-07-28 0

TTP MERGER SUB, INC.

  • 10% Owner
3,737,360 2020-07-28 0

LA JOLLA PHARMACEUTICAL HOLDINGS, LLC

  • 10% Owner
1,085,000 2020-07-23 0

MAHER ILLYA KEITH

  • Director
0 2020-01-22 0

FREUND JOHN GORDON

  • Director
0 2019-12-10 0

HENWOOD GERALDINE

  • Director
0 2019-06-10 0

BOHLIN GAREN G

  • Director
0 2019-06-10 0

WYSENSKI NANCY

  • Director
0 2019-06-10 0

CHODAKEWITZ JEFFREY

  • Director
0 2019-06-10 0

DUMAS JACQUES CHIEF SCIENTIFICOFFICER

  • Officer
0 2019-01-17 0

TSAI LARRY CHIEF MEDICAL OFFICER

  • Officer
31,503 2019-01-17 0

UNNINAYAR KAMALAM CHIEF FINANCIAL OFFICER

  • Officer
0 2018-01-17 0

HORN PATRICK TAYLOR CHIEF MEDICAL OFFICER

  • Officer
10,000 2017-06-13 0

THOMPSON JOHN CRAIG CHIEF OPERATING OFFICER

  • Officer
343 2015-09-08 0

LUBNER DAVID CHARLES SVP AND CFO

  • Officer
69,270 2015-08-14 0

GIROIR L. PATRICK JR.

  • INCORRECT PRIOR FILING
0 2015-06-10 0

FMR LLC

  • SEE REMARK 1
No longer subject to file 2015-03-05 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Get more info on our International short position coverage here

Holder Issuer Net Short Position Position Date Origin

Short Position History (International Only)

Holder Net Short Position Position Date Origin
Squarepoint Ops LLC Tetraphase Pharmaceuticals Inc 1.33% 2019-10-03 GERMANY
Squarepoint Ops LLC Tetraphase Pharmaceuticals Inc 0.83% 2019-10-10 GERMANY
Squarepoint Ops LLC Tetraphase Pharmaceuticals Inc 0.93% 2019-10-09 GERMANY
Squarepoint Ops LLC Tetraphase Pharmaceuticals Inc 1.23% 2019-10-04 GERMANY
Squarepoint Ops LLC Tetraphase Pharmaceuticals Inc 0.74% 2019-10-11 GERMANY
Squarepoint Ops LLC Tetraphase Pharmaceuticals Inc 0.54% 2019-10-14 GERMANY
Squarepoint Ops LLC Tetraphase Pharmaceuticals Inc 1.05% 2019-10-08 GERMANY
Squarepoint Ops LLC Tetraphase Pharmaceuticals Inc 1.41% 2019-10-01 GERMANY

Elevate your investments